[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548239":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":23,"studyPopulation":24,"armGroups":19,"interventions":19,"overallOfficials":25,"centralContacts":37,"locations":43,"responsibleParty":84,"collaborators":19,"id":86,"slug":19,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":19,"eligibilityCriteria":91,"healthyVolunteers":87,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":19,"studyType":98,"phases":19,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":45,"whyStopped":19,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"National Cancer Centre, Singapore","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":19},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Overall survival (OS)","Time from diagnosis to death.","Up to 10 years.",{"measure":14,"description":15,"timeFrame":12},"Duration of therapy (DOT)","Time from start of treatment regimen to end of treatment regimen.",{"measure":17,"description":18,"timeFrame":12},"Real-world progression-free survival (PFS)","Time from start of treatment regimen to disease progression or death.",null,{"allocation":19,"interventionModel":19,"interventionModelDescription":19,"primaryPurpose":19,"observationalModel":21,"timePerspective":22,"maskingInfo":19},"COHORT","RETROSPECTIVE","This study will be a multi-center observational study and will enroll patients with advanced EGFR exon 20 insertion mutated NSCLC.\n\nThe study will include patients recruited from countries across Asia, including sites in, but not limited to - Hong Kong, Korea, Singapore, Taiwan and Thailand. There will be approximately 20-30 sites recruiting for the study. In Singapore, sites may include National Cancer Centre Singapore (NCCS), National University Hospital (NUH) and Tan Tock Seng Hospital (TTSH).\n\nApproximately 600 patients will be enrolled retrospectively.","Patients with advanced EGFR exon 20 insertion mutated NSCLC.",[26,29,31,34],{"name":27,"affiliation":5,"role":28},"Aaron C. Tan, MBBS, PhD","STUDY_CHAIR",{"name":30,"affiliation":5,"role":28},"Daniel SW Tan, BSc, MBBS, PhD",{"name":32,"affiliation":33,"role":28},"Dong-Wan Kim, MD, MS, PhD","Seoul National University Hospital",{"name":35,"affiliation":36,"role":28},"Jin-Yuan Shih, MD, PhD","National Taiwan University Hospital",[38],{"name":39,"role":40,"phone":41,"phoneExt":19,"email":42},"Cherlyn Shepherdson","CONTACT","+65 6306 1748","cherlyn.shepherdson@nccs.com.sg",[44,61,72],{"facility":5,"status":45,"city":46,"state":19,"zip":47,"country":46,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Singapore","168583","SG",{"type":50,"coordinates":51},"Point",[52,53],103.85007,1.28967,{"lat":53,"lon":52},[56,59],{"name":27,"role":40,"phone":57,"phoneExt":19,"email":58},"+65 6436 8000","aaron.tan@singhealth.com.sg",{"name":30,"role":40,"phone":57,"phoneExt":19,"email":60},"daniel.tan.s.w@singhealth.com.sg",{"facility":33,"status":45,"city":62,"state":19,"zip":19,"country":63,"countryCode":19,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Seoul","South Korea",{"type":50,"coordinates":65},[66,67],126.9784,37.566,{"lat":67,"lon":66},[70],{"name":71,"role":40,"phone":19,"phoneExt":19,"email":19},"Dong-Wan Kim",{"facility":36,"status":45,"city":73,"state":19,"zip":19,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Taipei","Taiwan","TW",{"type":50,"coordinates":77},[78,79],121.52639,25.05306,{"lat":79,"lon":78},[82],{"name":83,"role":40,"phone":19,"phoneExt":19,"email":19},"Jin-Yuan Shih",{"type":85,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100548239",false,"NCT06418412","A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC","A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated Non-small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n1. Histologically confirmed advanced NSCLC\n2. Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation\n3. Diagnosis date from 1 Jan 2013 to 31 Dec 2024 (to allow for minimum 12 months of follow-up clinical and treatment outcome data)\n4. Male or female adults, age as defined by local regulations\n\nExclusion Criteria:\n\n1\\. Patients without an EGFR exon 20 insertion mutation","ALL","21 Years","99 Years",{"count":96,"type":97},600,"ESTIMATED","OBSERVATIONAL","There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies.\n\nThis study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.",[101],"Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer",[103,104],"EGFR EXON20 insertion","NSCLC (Non small cell lung cancer)","2025-06-11",{"date":107,"type":108},"2025-06-12","ACTUAL",{"date":110,"type":108},"2024-03-15",{"date":112,"type":97},"2026-12-31",{"name":5,"class":6},3]